Overview: KIR Genotyping TestIntroduction: The KIR Genotyping Test identifies KIR genes to assess transplant compatibility, reducing rejection risk. Aligned with 2023 ASHI guidelines, it uses PCR for high specificity, supporting transplant screening. This test is critical for guiding transplant planning, donor selection, and improving outcomes in molecular pathology for patients undergoing transplantation.
Other Names: KIR Genotyping Assay, Transplant Compatibility Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: KIR genotyping began in the 2000s with transplant immunology research. PCR-based methods improved in the 2010s, enhancing compatibility assessment.
Purpose: Identifies KIR genes to assess transplant compatibility, guides donor selection, and reduces rejection risk.
Test Parameters: 1. KIR Genotype
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of transplant or rejection episodes.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document transplant history, rejection episodes, or family history of transplant complications. Include current medications, especially immunosuppressants.
Consent: Written consent required, detailing the tests purpose, transplant implications, and risks of blood or swab collection.
Procedural Considerations: Uses PCR to identify KIR genes in whole blood, buccal swab, or saliva. Results are available in 3-5 days, supporting transplant planning. Performed in laboratories, often for donor compatibility.
Factors Affecting Result Accuracy: Improper sample storage or contamination can affect results. Low DNA yield may reduce sensitivity.
Clinical Significance: Specific KIR genotypes indicate compatibility, guiding donor selection. Incompatible genotypes increase rejection risk, requiring alternative donors.
Specialist Consultation: Consult a transplant immunologist or hematologist for result interpretation and donor selection.
Additional Supporting Tests: HLA typing, MICA genotyping, or flow cytometry to assess transplant compatibility.
Test Limitations: Not predictive of all rejection risks; clinical correlation is needed. KIR variability requires careful interpretation.
References: ASHI Transplant Guidelines, 2023; Transplantation, Middleton D, 2022.
